What is pathophysiology of Alzheimer?

['Phulaphula eli phepha']

Yintoni i-pathophysiology ye-Alzheimer?

Ipathophysiology yesifo sika-Alzheimer (AD) yinkqubo entsonkothileyo ebandakanya ukuqokelelana kweeprotini ezingaqhelekanga, ukudumba nokungasebenzi kakuhle kwemithambo-luvo.

Iimpawu ezimbini eziphambili ze-AD bubukho beeplaque ze-amyloid-beta (Aβ) ne-neurofibrillary tangles (NFTs) kwingqondo.

Iiplaque ze-Amyloid-beta zenziwa xa iziqwenga zeprotein ye-amyloid precursor (APP) zikhutshwa zii-enzymes ukuze zenze ii-Aβ peptides.

Ezi peptide zidibanisa zize zenze i-insoluble fibrils eziqokelela ngaphandle kweeseli zemithambo-luvo, ziphazamise unxibelelwano lweeseli phakathi kwazo zikhokelele ekufeni kweeseli zemithambo-luvo.

Ukuqokelelana kwee-Aβ plaques kucingelwa ukuba yenye yeziganeko zokuqala ekuphuhlisweni kwe-AD, yaye kukholelwa ukuba kunegalelo kwinkqubo yokuwohloka kwemithambo-luvo.

Iintambo ze-neurofibrillary zenziwa xa iproteni ye-tau iba yi-hyperphosphorylated ize yenze imisonto engaqhelekanga ngaphakathi kwii-neurons.

Ezi zinto zidibeneyo ziphazamisa ukusebenza kwee-microtubules, eziyimfuneko ukuze kuthuthwe izondlo nezinye izinto ngaphakathi kwinuron.

Ekugqibeleni ezi zinto zidibeneyo zikhokelela ekufeni kweeseli zemithambo-luvo ezichaphazelekayo.

Ukudumba kukwadlala indima kwipathophysiology ye-AD.

Inkqubo yomzimba yokuzikhusela isabela ekuqokeleleni kweeplaques ze-Aβ nee-NFTs ngokukhupha ii-cytokines ezibangela ukudumba, ezinokuyenza mandundu ingozi kwiineurons.

Ukongeza, kukho ubungqina bokuba uxinzelelo lwe-oxidative, ukungasebenzi kakuhle kwe-mitochondrial, kunye nokuphazamiseka kwe-glucose metabolism zinegalelo kwi-pathophysiology ye-AD.

Ezi zinto zinokubangela ukuba iiseli zingasebenzi kakuhle zize zife, nto leyo ebangela ukuba esi sifo sihambele phambili.

Xa kuthethwa nje ngokubanzi, i-pathophysiology ye-AD yinkqubo entsonkothileyo yokunxibelelana kwezinto ezininzi ezikhokelela ekuwohlokeni kwengqondo nokulahleka kwenkumbulo okubonisa esi sifo.

['Iimbekiselo']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nemeroff CB: The preeminent role of neuropeptide systems in the early pathophysiology of Alzheimer disease: up with corticotropin-releasing factor, down with acetylcholine. Arch Gen Psychiatry. 1999, 56 (11): 991-2.

Skoog I, Kalaria RN, Breteler MM: Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord. , 13 Suppl 3 (): S106-14.

Proft J, Weiss N: Jekyll and Hide: The two faces of amyloid β. Commun Integr Biol. 2012, 5 (5): 405-7.

Whitehouse PJ, Hedreen JC, White CL, Price DL: Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol. 1983, 13 (3): 243-8.

Casadesus G, Moreira PI, Nunomura A, Siedlak SL, Bligh-Glover W, Balraj E, Petot G, Smith MA, Perry G: Indices of metabolic dysfunction and oxidative stress. Neurochem Res. , 32 (4-5): 717-22.

Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Di Bona D, Duro G, Lio D, Matranga D, Pellicanò M, Rizzo C, Scapagnini G, Vasto S: Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenation Res. , 13 (2-3): 301-13.

Raskind MA, Peskind ER: Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease. Alzheimer Dis Assoc Disord. 1994, 8 Suppl 3 (): 54-60.

Schindler SE, McConathy J, Ances BM, Diamond MI: Advances in diagnostic testing for Alzheimer disease. Mo Med. , 110 (5): 401-5.

Singh VK: Immune-activation model in Alzheimer disease. Mol Chem Neuropathol. , 28 (1-3): 105-11.

['Ukuzikhusela: unyango']

['Le webhsayithi yenzelwe ukufundisa nokunika inkcazelo kuphela yaye ayibonisi ukuba inikela amacebiso ezonyango okanye iinkonzo zobungcali.']

['Inkcazelo enikelweyo ayifanele isetyenziselwe ukuxilonga okanye ukunyanga ingxaki yempilo okanye isifo, yaye abo bafuna icebiso lonyango lobuqu bafanele babonane nogqirha onelayisensi.']

['Nceda uqaphele ukuba inethiwekhi ye-neural eyenza iimpendulo kwimibuzo, ayichanekanga xa kufikwa kumxholo wenani. Umzekelo, inani labantu abafunyaniswe benesifo esithile.']

['Soloko ucela icebiso kugqirha wakho okanye komnye umboneleli wezempilo ofanelekileyo malunga nemeko yakho yezonyango. Ungaze ungayihoyi ingcebiso yezonyango okanye ulibazise ukufuna ngenxa yento oyifunde kule webhusayithi. Ukuba ucinga ukuba unengxaki yezonyango, tsalela umnxeba ku-911 okanye uye kwigumbi likaxakeka elikufutshane ngoko nangoko. Akukho buhlobo bukagqirha nomguli obudalwa yile webhusayithi okanye ukusetyenziswa kwayo. I-BioMedLib okanye abasebenzi bayo, okanye nabani na onegalelo kule webhusayithi, abenzi zimelo, ngokucacileyo okanye ngokungangqalanga, ngokubhekisele kulwazi olunikezwe apha okanye ekusetyenzisweni kwalo.']

['Ukuzikhulula: ilungelo lokushicilela']

['Umthetho we-Digital Millennium Copyright ka-1998, 17 U.S.C. § 512 (i-DMCA) ubonelela ngeendlela zokubhena kubanini bamalungelo obunini abakholelwa ukuba izinto ezibonakala kwi-Intanethi ziphula amalungelo abo phantsi komthetho welungelo lokushicilela wase-US. ']

['Ukuba ukholelwa ukuba kukho umxholo okanye izinto ezenziwe zafumaneka kwi-website yethu okanye iinkonzo eziphula ilungelo lakho lokushicilela, wena (okanye iarhente yakho) ungathumela isaziso esicela ukuba umxholo okanye izinto zisuswe, okanye ukufikelela kuzo kuvalwe. ']

['Izaziso kufuneka zithunyelwe ngokubhaliweyo nge-imeyile (jonga kwicandelo elithi "Qhagamshelana" ukuze ufumane idilesi ye-imeyile).']

['I-DMCA ifuna ukuba isaziso sakho sokutyholwa ngokophula ilungelo lokushicilela siquke ezi nkcukacha zilandelayo: (1) inkcazelo yomsebenzi onelungelo lokushicilela ongundaba-mlonyeni wokutyholwa ngokophula; (2) inkcazelo yomxholo otyholwa ngokophula kunye nolwazi olwaneleyo ukusivumela ukuba sifumane umxholo; (3) iinkcukacha zokuqhagamshelana nawe, kuquka idilesi yakho, inombolo yomnxeba nedilesi ye-imeyile; (4) ingxelo yakho yokuba unokholo olulungileyo lokuba umxholo ngendlela ekhalazwa ngayo awugunyaziswanga ngumnini welungelo lokushicilela, okanye iarhente yakhe, okanye ngokusebenza kwawo nawuphi na umthetho; ']

['(5) ingxelo yakho, esayinwe phantsi kwesohlwayo sobuxoki, yokuba ulwazi olukwisibhengezo luchanekile kwaye unegunya lokunyanzelisa amalungelo okushicilela ekuthiwa aphulwe;']

['kwaye (6) utyikityo lomzimba okanye lwe-elektroniki lomnini welungelo lokushicilela okanye lomntu ogunyazisiweyo ukuba enze egameni lomnini welungelo lokushicilela. ']

['Ukungabandakanyi lonke ulwazi olungentla kungakhokelela ekulibaziseni ukuphathwa kwesikhalazo sakho.']

['Unxibelelwano']

['Nceda usithumelele i-imeyile ngayo nayiphi na imibuzo / iingcebiso.']

What is pathophysiology of alzheimer?

The pathophysiology of Alzheimer's disease (AD) is a complex process that involves the accumulation of abnormal proteins, inflammation, and neuronal dysfunction.

The two main hallmarks of AD are the presence of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) in the brain.

Amyloid-beta plaques are formed when fragments of the amyloid precursor protein (APP) are cleaved by enzymes to form Aβ peptides.

These peptides aggregate and form insoluble fibrils that accumulate outside neurons, disrupting cell-to-cell communication and leading to neuronal death.

The accumulation of Aβ plaques is thought to be one of the earliest events in the development of AD, and it is believed to contribute to the neurodegenerative process.

Neurofibrillary tangles are formed when the protein tau becomes hyperphosphorylated and forms abnormal filaments inside neurons.

These tangles disrupt the normal functioning of the microtubules, which are essential for the transport of nutrients and other materials within the neuron.

The tangles eventually lead to the death of the affected neurons.

Inflammation also plays a role in the pathophysiology of AD.

The immune system responds to the accumulation of Aβ plaques and NFTs by releasing pro-inflammatory cytokines, which can exacerbate the damage to neurons.

Additionally, there is evidence that oxidative stress, mitochondrial dysfunction, and impaired glucose metabolism contribute to the pathophysiology of AD.

These factors can lead to neuronal dysfunction and death, further exacerbating the disease process.

Overall, the pathophysiology of AD is a complex interplay of multiple factors that ultimately lead to the progressive decline in cognitive function and memory loss that characterizes the disease.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.